Role of animal models in the study of drug-induced hypersensitivity reactions

AAPS Journal

Volumn 7, Issue 4, 2006, Pages

  Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Animal models; Hypersensitivity reactions; Idiosyncratic drug reactions; Nevirapine; Penicillamine; Popliteal lymph node assay

Indexed keywords

1 AMINOBENZOTRIAZOLE; AMINOGUANIDINE; AMODIAQUINE; ANTIMALARIAL AGENT; CYCLOSPORIN; CYTOCHROME P450; HALOTHANE; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; LIPOPOLYSACCHARIDE; METHYLDOPA; MISOPROSTOL; NEVIRAPINE; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; POLYINOSINIC POLYCYTIDYLIC ACID; PROPYLTHIOURACIL; PROSTAGLANDIN E; RANITIDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFAMETHOXAZOLE; SULFONAMIDE; TACROLIMUS; DRUG;

AGRANULOCYTOSIS; AMNESIA; ANIMAL DISEASE; ANIMAL MODEL; ARTHRITIS; ARTHROPATHY; AUTOIMMUNITY; BODY WEIGHT DISORDER; BREEDING; CAT DISEASE; CLINICAL STUDY; COOMBS POSITIVE HEMOLYTIC ANEMIA; DOG DISEASE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EXPERIMENTAL MODEL; FEVER; GUINEA PIG; HEMOLYTIC ANEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; HYPOXIA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTOXICITY; INCIDENCE; KERATOCONJUNCTIVITIS SICCA; LETHARGY; LEUKOPENIA; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LUPUS LIKE SYNDROME; LYMPH NODE; MEDICAL RESEARCH; METABOLITE; MOUSE; MYASTHENIA GRAVIS; NEUTROPENIA; NONHUMAN; PEMPHIGUS; PROSPECTIVE STUDY; PROTEIN SYNTHESIS INHIBITION; RAT; REVIEW; RHEUMATOID ARTHRITIS; SCREENING TEST; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; WILSON DISEASE; ANIMAL; CAT; DISEASE MODEL; IMMUNOLOGY; RABBIT;

ANIMALS; CATS; DISEASE MODELS, ANIMAL; DRUG HYPERSENSITIVITY; GUINEA PIGS; PHARMACEUTICAL PREPARATIONS; RABBITS; RATS;

EID: 33747126524     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070489     Document Type: Review

References (50)

1. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol. 1999;112:387-395. PubMed DOI: 10,1021/tx9802491
2. Knowles SR, Uetrecht JP, Shear NH. Confirming false adverse reactions to drugs by performing individualized, randomized trials. Can J Clin Pharmacol. 2002;9:149-1153. PubMed
3. Macy E. Multiple antibiotic allergy syndrome, Immunol Allergy Clin North Am. 2004;24:533-543. PubMed DOI: 10.1016/j.iac.2004.03.002
4. Jaffe IA. Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases, Springer Semin Immunopathol. 1981;4:193-207. PubMed DOI: 10.1007/BF01857095
5. Weiss AS, Markenson JA, Weiss MS, Kammerer WH. Toxicity of D-penicillamine in rheumatoid arthritis: a report of 63 patients including 2 with aplastic anemia and one with the nephrotic syndrome. Am J Med. 1978;64:114-120. PubMed DOI: 10.1016/0002-9343(78)90186-9
6. Stein HB,. Patterson AC, Offer RC, Atkins CJ, Teufel A, Robinson HS. Adverse effects of D-penicillamine in rheumatoid arthritis. Ann Intern Med. 1980;92:24-29. PubMed
7. Donker AJ, Venuto RC, Vladutiu AO, Brentjens JR, Andres GA. Effects of prolonged administration of D-penicillamine or captopril in various strains of rats. Clin Immunol Immunopathol. 1984;30:142-155. PubMed DOI: 10.1016/0090-1229(84)90015-1
8. 2-induced autoimmunity. J Immunol. 1990; 144:2985-2991. PubMed
9. Masson MJ, Uetrecht JP. Tolerance induced by low dose D-penicillamine in the Brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem Res Toxicol. 2004;17:82-94. PubMed DOI: 10.1021/ tx034195a
10. Seguin B, Masson MJ, Uetrecht J. D-penicillamine-induced autoimmunity in the Brown Norway rat: role for both T and non-T splenocytes in adoptive transfer of tolerance. Chem Res Toxicol. 2004;17:1299-1302. PubMed DOI: 10.1021/tx0498399
11. Sayeh E, Uetrecht JP. Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1/Th2 paradigm. Toxicology. 2001;163:195-211 PubMed DOI: 10.1016/S0300-483X(01)00385-7
12. Seguin B, Boutros PC, Li X, Okey AB, Uetrecht JP. Gene expression profiling in a model of d-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger. Chem Res Toxicol, 2005;18:1193-1202. PubMed DOI: 10.1021/tx050040m
13. Masson MJ, Teranishi M, Shenton JM, Uetrecht JP. Investigation of the involvement of macrophages and T cells in D-penicillamine-induced autoimmunity in the Brown Norway rat. J Immunotoxicol. 2004;1:79-93. PubMed DOI: 10.1080/15476910490496258
14. Rhodes J. Evidence for an intercellular covalent reaction essential in antigen-specific. T cell activation. J Immunol. 1989;143:1482-1489. PubMed
15. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev. 2005;4:3109-314. PubMed DOI: 10.1016/j.autrev.2005.01.002
16. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32:124-129. PubMed DOI: 10.1086/ 317536
17. Shenton JM. Teranishi M. Abu-Asab MS. Yager JA. Uetrecht JP. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem Res Toxicol. 2003;16:1078-1089. PubMed DOI: 10.1021/tx034064+
18. Shenton JM, Popovic M, Chen J, Masson MJ, Uetrecht JP. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female brown norway rat. Chem Res Toxicol. 2005;18:1799-1813. PubMed DOI: 10.1021/tx0501132
19. Aucoin DP, Peterson ME, Hurvitz AI, et al. Propylthiouracil-induced immune-mediated disease in the cat. J Pharmacol Exp Ther. 1985;234:13-18. PubMed
20. Aucoin DP, Rubin RL, Peterson ME, et al. Dose-dependent induction of antinative DNA antibodies in cats by propylthiouracil. Arthritis Rheum. 1988;31.688-692. PubMed
21. Waldhauser L, Uetrecht J. Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat. Toxicology. 1996;114:155-162. PubMed DOI: 10.1016/SO300-483X(96)03476-2
22. Waldhauser L, Uetrecht J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils: implications for agranulocytosis. Drug Metab Dispos. 1991;19:354-359. PubMed
23. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes; an overview, Semin Arthritis Rheum. 1999;28:392-397. PubMed DOI: 10.1016/ S0049-0172(99)80004-3
24. Nässberger L, Sjöholm AG, Jonssen H, Sturfelt G, Åkesson A. Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol. 1990:81:380-383. PubMed
25. Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther. 2004:27:129-138. PubMed DOI: 10.1111/j.1365-2885.2004.00576.x
26. Zimmerman H. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, PA: Lippincott Williams & Wilkins; 1999.
27. Kenna JG, Neuberger J, Williams R. Identification by immunoblotting of 3 halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J Pharmacol Exp Ther. 1987;242:733-740. PubMed
28. Satoh H. Martin BM, Schulick AH, Christ DD, Kenna JG, Pohl LR. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc Natl Acad Sci USA. 1989;86:322-326. PubMed
29. Bourdi M, Chen W., Peter RM. et al. Human cytochrome P450F1 is a major autoantinen associated with halothane hepatitis. Chem Res Toxicol. 1996;9:1159-1166. PubMed DOI: 1.1021/tx960083q
30. McLain GE, Sipes IG, Brown BR. An animal model of halothane hepatotoxicity: roles of enzyme induction and hypoxia. Anesthesiology. 1979;51:321-326 PubMed
31. Furst SM, Luedke D, Gaw HH, Reich R, Gandolfi AJ. Demonstration of a cellular immune response in halothane-exposed guinea pigs, Toxicol Appl Pharmacol. 1997; 143-245-255. PubMed DOI: 10.1006/taap.1996.8093
32. Maggs JL, Tingle MD, Kitteringham NR, Park BK. Drug-protein conjugates-XIV: mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin, and hepatoxin in man. Biochem, Pharmacol. 1988;37:303-311. PubMed DOI: 10.1016/ 0006-2952(88)90733-2
33. Clarke JB, Neftel K, Kitteringham NR, Park BK. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol. 1991;95:369-375. PubMed
34. Clarke JB, Maggs JL, Kitteringham NR, Park BK. Immunogenicity of amodiaquine in the rat. Int Arch Allergy Appl Immunol. 1990;91:335-342. PubMed
35. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatotoxidity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther. 1980;213:364-369. PubMed
36. Sarich TC, Zhou T. Adams SP, Bain AI, Wall RA, Wright JM. A model of isoniazid-induced hepatotoxicity in rabbits. J Pharmacol Toxicol Methods. 1995;34,109-116. PubMed DOI: 10.1016/1056-8719(95)00044-1
37. Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003;307:9-16. Pub-Med DOI: 10.1124/jpet.103.054288
38. Luyendyk JP, Shaw PJ, Green CD, Maddox JF, Ganey PE. Roth RA, Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther. 2005;314:1023-1031. PubMed DOI: 10.1124/jpet.105.087981
39. Roth RA, Luyendyk JP, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy: is there a connection? J Pharmacol Exp Ther.2003;307:1-8. PubMed DOI: 10.1124/jpet.102-041624
40. Pieters R, Ezendam J, Bleumink R, Bol M, Nierkens S. Predictive testing for autoimmunity. Toxicol Lett. 2002;127:83-91. PubMed DOI: 10.1016/ SO378-4274(01)00487-8
41. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug protein adducts: and industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004;17:3-16, PubMed DOI: 10,1021/tx034170b
42. Bloksma N, Kubicka-Muranyi M, Schuppe H, Gleichmann E, Gleichmann H. Predictive immunotoxicological test systems: suitability of the popliteal lymph node assay in mice and rats. Crit Rev Toxicol. 1995;25:369-396. PubMed
43. Gutting BW, Schomaker SJ, Kaplan AH, Amacher DE. A comparison of the direct and reporter antigen popliteal lymph node assay for the detection of immunomodulation by low molecular weight compounds. Toxicol Sci. 1999;51:71-79, PubMed DOI: 10.1093/toxsci/51.1.71
44. Nierkens S, Nieuwenhuijsen L, Thomas M, Pieters R. Evaluation of the use of reporter antigens in an auricular lymph node assay to assess the immunosensitizing potential of drugs. Toxicol Sci. 2004;79:90-97. PubMed DOI: 10,1093/toxsci/kfh074
45. Roychowdhury S, Vyas PM, Reilly TP, Gaspari AA, Svensson CK. Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes, J Pharmacol Exp Ther. 2005;314:43-52. PubMed DOI: 10.1124/ jpet.105.086009
46. Kammuller ME, Seinen W. Structural requirements for hydantoins and 2-thiohydantoins to induce lymphoproliferative popliteal lymph node reactions in the mouse. Int J Immunopharmacol. 1988;10:997-1010. PubMed DOI: 10.1016/0192-0561 (88)90047-1
47. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated Molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004;4:469-478. PubMed DOI: 10.1038/nri1372
48. Wooley PH, Whalen JD. Pristane-induced arthritis in mice. III. Lymphocyte phenotypic and functional abnormalities precede the development of pristane-induced arthritis, Cell Immunol. 1991; 138:251-259. PubMed DOI: 10.1016/0008-8749(91)90150-A
49. Albers R, Broeders A, van der Pijl A, Seinen W, Pieters R. The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Toxicol Appl Pharmacol. 1997; 143:102-109. PubMed DOI: 10.1006/taap.1996.8078
50. Nierkens S, Aalbers M, Bol M, van Wijk F, Hassing I, Pieters R. Development of an oral exposure mouse model to predict drug-induced hypersensitivity reactions by using reporter antigens. Toxicol Sci. 2005;83:273-281. PubMed DOI: 10.1093/toxsci/kfi021